Becton Dickinson and (NYSE:BDX)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Jaffray Companies in a research report issued to clients and investors on Tuesday, The Fly reports. They presently have a $260.00 price target on the medical instruments supplier’s stock, up from their prior price target of $223.00. Piper Jaffray Companies’ price target would indicate a potential upside of 14.28% from the stock’s current price.
A number of other equities analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday, January 12th. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Royal Bank of Canada restated a “hold” rating and set a $210.00 price objective on shares of Becton Dickinson and in a research note on Wednesday, October 25th. Stifel Nicolaus restated a “buy” rating and set a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, KeyCorp initiated coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Buy” and an average price target of $236.93.
Shares of Becton Dickinson and (NYSE:BDX) traded up $2.70 during midday trading on Tuesday, reaching $227.52. 2,876,197 shares of the company were exchanged, compared to its average volume of 1,539,912. The firm has a market cap of $51,580.00, a price-to-earnings ratio of 49.33, a PEG ratio of 1.69 and a beta of 1.12. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. Becton Dickinson and has a 12-month low of $175.66 and a 12-month high of $248.39.
Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Becton Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after acquiring an additional 1,353,780 shares during the period. State Street Corp raised its holdings in Becton Dickinson and by 3.5% in the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after acquiring an additional 342,873 shares during the period. Northern Trust Corp raised its holdings in Becton Dickinson and by 4.0% in the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after acquiring an additional 106,966 shares during the period. Fiera Capital Corp raised its holdings in Becton Dickinson and by 7.1% in the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock valued at $542,825,000 after acquiring an additional 183,372 shares during the period. Finally, Fundsmith LLP raised its holdings in Becton Dickinson and by 0.3% in the 2nd quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock valued at $449,258,000 after acquiring an additional 5,977 shares during the period. 75.68% of the stock is currently owned by institutional investors.
WARNING: “Piper Jaffray Companies Reaffirms “Overweight” Rating for Becton Dickinson and (BDX)” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/06/piper-jaffray-companies-reaffirms-overweight-rating-for-becton-dickinson-and-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.